Copyright
©The Author(s) 2016.
World J Gastroenterol. Sep 21, 2016; 22(35): 7951-7962
Published online Sep 21, 2016. doi: 10.3748/wjg.v22.i35.7951
Published online Sep 21, 2016. doi: 10.3748/wjg.v22.i35.7951
Table 1 Deregulated miRNA in gastric cancer tumor
miRNA/role | Targets | Clinicopathological features | Ref. |
OncomiRNAs | |||
miR-17 | UBE2C | Tumor size | [21-24] |
FBXO31 | Tumor infiltration | ||
Clinical grade | |||
Prognosis | |||
Tumor stage | |||
mir-19a | MXD1 | Migration | [25-28] |
SOCS1 | Invasion | ||
PTEN | Metastasis | ||
Proliferation | |||
Multidrug resistance | |||
miR-20a | EGR2 | Overall survival | [29-31] |
E2F1 | Relapse-free survival | ||
Self-renewal and proliferation of GC stem cells | |||
Chemoresistance of GC cells to cisplatin and docetaxel | |||
miR-21 | PTEN | Differentiation | [29,32-37] |
PDCD4 | Lymph node metastasis | ||
RECK | H. pylori infection | ||
SERPINI1 | Tumor stage | ||
Tumor size | |||
miR-25 | FBXW7 | Proliferation | [38-41] |
TOB1 | Invasion | ||
RECK | Migration | ||
Metastasis | |||
Aggressive phenotype | |||
Poor long-term survival | |||
miR-27a | PHB | H. pylori infection | [42-44] |
ZBTB10 | Proliferation | ||
HOXA10 | Drug resistance | ||
CCND1 | |||
miR-106a | TIMP2 | Invasion | [45-50] |
PTEN | Differentiation | ||
FAS | Distant metastasis | ||
RUNX3 | Lymph node metastasis | ||
Tumor stage | |||
Tumor size | |||
miR-106b | P21 | Lymph node metastasis | [29,46,51-54] |
E2F5 | Depth of infiltration | ||
E2F1 | |||
miR-200b | ZEB1 | Diffuse-type | [55-58] |
ZEB2 | Poor overall survival | ||
SUZ12 | H. pylori infection | ||
DNMT3A | Metastasis | ||
DNMT3B | Tumor size | ||
SP1 | |||
WNT-1 | |||
miR-215 | RB1 | Tumor stage | [59-61] |
RUNX1 | |||
miR-222 | PTEN | Shorter metastasis-free survival | [38,62-65] |
RECK | Proliferation | ||
tsmiRNAs | |||
let-7a | RAB40C | Differentiation | [66-71] |
CDKN1 | Lymph node metastasis | ||
SPHK2 | Cell cicle arrest | ||
FN1 | Growth suppression | ||
Overall survival | |||
Relapse-free survival | |||
miR-143 | COX-2 | Invasion | [69,72-75] |
Haematogenous metastasis | |||
Lymph node metastasis | |||
Tumor stage | |||
miR-148a | ROCK1 | Clinical stage | [76-80] |
MMP7 | Lymph node metastasis | ||
p27 | Poor clinical outcome | ||
DNMT1 | Epithelial-mesenchymal transition | ||
SMAD4 | |||
miR-200c | RND3 | Lymph node metastasis | [56,57,81,82] |
DNMT3A | Poor overall survival | ||
DNMT3B | Sensitivity of chemotherapy to cisplatin | ||
SP1 | Clinical stage | ||
Invasion | |||
miR-204 | SIRT1 | Epithelial-mesenchymal transition | [83-85] |
BCL-2 | Anoikis resistance | ||
EZR | Migration | ||
Invasion | |||
Colony forming ability | |||
miR-218 | VOPP1 | Proliferation | [86-89] |
ROBO1 | Migration | ||
Metastasis | |||
miR-433 | RAB34 | Tumor stage | [90-92] |
KRAS | Overall survival | ||
Proliferation | |||
Migration | |||
Invasion | |||
Controversial | |||
miR-9 | CCND1 | Proliferation | [90,93-96] |
ETS1 | Invasion | ||
CDX2 | Metastasis | ||
GRB2 | |||
NF-kappaB1 | |||
RAB34 | |||
miR-107 | FOXO1 | Invasion | [97-100] |
DICER1 | Differentiation | ||
CDK6 | Lymph node metastasis | ||
Tumor size | |||
Tumor stage | |||
Overall survival | |||
miR-146a | EGFR | Tumor size | [101-106] |
IRAK1 | Poor differentiation | ||
L1CAM | |||
CARD1O | Lymph node metastasis | ||
COPS8 | Venous invasion | ||
NASF2 | Overall survival time | ||
SMAD4 | Apoptosis | ||
WASF2 | |||
miR-155 | SMAD2 | Invasion | [38,107-111] |
CDC73 | Lymph node metastasis | ||
CYCLIN D1 | H. pylori infection | ||
Cell viability | |||
Apoptosis | |||
miR-181b | CREB1 | Proliferation | [112-115] |
BCL2 | Migration | ||
Invasion | |||
Colony formation | |||
Apoptosis | |||
Multidrug resistance | |||
miR-223 | EPB4IL3 | Poor metastasis-free survival | [116-118] |
STMN1 | Apoptosis | ||
FBXW7 | Proliferation | ||
Invasion | |||
HMGA2 | Poor clinical prognosis |
Table 2 Circulating miRNA as diagnostic and prognostic biomarkers
miRNA | Samples | Potential biomarker type | Method | Clinical implication | Ref. |
miR-1 | 164 GC/127 C Serum | Diagnostic | Solexa sequencing | GC detection | [128] |
qRT-PCR | |||||
miR-16 | 40 GNCA/40 C Plasma | Diagnostic | Taqman low-density array | Early detection of GNCA | [122] |
qRT-PCR | |||||
miR-17-5p | 79 GC/30 C Plasma | Diagnostic | qRT-PCR | GC detection | [46] |
79 pre-operative GC/30 post-operative GC/6 relapse Plasma | Prognostic | qRT-PCR | Prediction of prognosis and monitoring of chemotherapeutic effects | [129] | |
miR-18a | 104 GC/65 C Plasma | Diagnostic | qRT-PCR | Screening GC and monitoring tumor dynamics | [130] |
Prognostic | |||||
miR-20a | 164 GC/127 C Serum | Diagnostic | Solexa sequencing | GC detection | [128] |
qRT-PCR | |||||
90 GC/90 C Plasma | Diagnostic | qRT-PCR | Early detection of GC | [131] | |
79 pre-operative GC/30 post-operative GC/6 relapse Plasma | Prognostic | qRT-PCR | Prediction of prognosis and monitoring of chemotherapeutic effects | [129] | |
miR-21 | 69 GC Plasma | Prognostic | qRT-PCR | Prognostic marker | [132] |
16 LN-metastasis positive/15 LN-metastasis negative/10 C Serum | Prognostic | qRT-PCR | Predicting LN metastasis | [133] | |
79 GC/30 C Plasma | Diagnostic | qRT-PCR | GC detection | [46] | |
70 GC/70 C Plasma | Diagnostic | qRT-PCR | GC detection | [134] | |
miR-25 | 40 GNCA/40 C Plasma | Diagnostic | Taqman low-density array | Early detection of GNCA | [122] |
qRT-PCR | |||||
miR-34 | 164 GC/127 C Serum | Diagnostic | Solexa sequencing | GC detection | [128] |
qRT-PCR | |||||
miR-92a | 40 GNCA/40 C Plasma | Diagnostic | Taqman low-density array | Early detection of GNCA | [122] |
qRT-PCR | |||||
miR-106a | 79 GC/30 C Plasma | Diagnostic | qRT-PCR | GC detection | [46] |
miR-106b | 79 GC/30 C Plasma | Diagnostic | qRT-PCR | GC detection | [46] |
90 GC/90 C Plasma | Diagnostic | qRT-PCR | Early detection of GC | [131] | |
miR-191 | 57 GC/58 C Serum | Diagnostic | qRT-PCR | GC detection | [135] |
miR-218 | 70 GC/70 C Plasma | Diagnostic | qRT-PCR | GC detection | [134] |
miR-221 | 90 GC/90 C Plasma | Diagnostic | qRT-PCR | Early detection of GC | [131] |
miR-223 | 70GC/70C Plasma | Diagnostic | qRT-PCR | GC detection | [134] |
miR-378 | 61GC/61C Serum | Diagnostic | miRNA microarray | Early detection of GC | [136] |
qRT-PCR | |||||
miR-423-5p | 164GC/127C Serum | Diagnostic | Solexa sequencing | GC detection | [128] |
qRT-PCR | |||||
miR-451 | 56GC/30C Plasma | Diagnostic | miRNA microarray | Screening GC | [137] |
qRT-PCR | |||||
40GNCA/40C Plasma | Diagnostic | Taqman low-density array | Early detection of GNCA | [122] | |
qRT-PCR | |||||
miR-486 | 56GC/30C Plasma | Diagnostic | miRNA microarray | GC Screening | [137] |
qRT-PCR | |||||
miR-486-5p | 40GNCA/40C Plasma | Diagnostic | Taqman low-density array | Early detection of GNCA | [122] |
qRT-PCR | |||||
let-7a | 79GC/30C Plasma | Diagnostic | qRT-PCR | GC detection | [46] |
Table 3 miRNA related to the risk of gastric cancer
miRNA | SNP | Country | Population | Number of cases/controls | Ref. |
miR-27a | rs895819 | China | Asian | 304/304 | [43] |
China | Asian | 295/413 | [154] | ||
China | Asian | 278/278 | [155] | ||
rs11671784 | China | Asian | 892 /978 | [156] | |
China | Asian | 278/278 | [155] | ||
miR-146a | rs2910164 | China | Asian | 304/304 | [157] |
Japan | Asian | 583/1637 | [158] | ||
Japan | Asian | 90/90 | [101] | ||
China | Asian | 1686/1895 | [159] | ||
South Korea | Asian | 461/447 | [160] | ||
Japan | Asian | 552/697 | [161] | ||
miR-196a | rs11614913 | Japan | Asian | 552/697 | [161] |
China | Asian | 213/213 | [162] | ||
South Korea | Asian | 461/447 | [160] | ||
Greece | Greak | 163/480 | [163] | ||
miR-499 | rs3746444 | Japan | Asian | 697/552 | [161] |
South Korea | Asian | 461/447 | [160] | ||
China | Asian | 363/969 | [164] | ||
miR-149 | rs2292832 | China | Asian | 274/269 | [165] |
South Korea | Asian | 461/447 | [160] | ||
Greece | Greak | 163/480 | [163] | ||
miR-24 | rs4819388 | China | Asian | 183/348 | [166] |
miR-570 | rs4143815 | China | Asian | 205/393 | [167] |
miR-200c | rs12904 | China | Asian | 522/501 | [168] |
miR-505 | rs111638916 | China | Asian | 857/748 | [169] |
Pre-miR-30c | rs928508 | China | Asian | 240/240 | [170] |
Pri-let-7a-2 | rs629367 | China | Asian | 107/124 | [171] |
- Citation: da Silva Oliveira KC, Thomaz Araújo TM, Albuquerque CI, Barata GA, Gigek CO, Leal MF, Wisnieski F, Rodrigues Mello Junior FA, Khayat AS, de Assumpção PP, Rodriguez Burbano RM, Smith MC, Calcagno DQ. Role of miRNAs and their potential to be useful as diagnostic and prognostic biomarkers in gastric cancer. World J Gastroenterol 2016; 22(35): 7951-7962
- URL: https://www.wjgnet.com/1007-9327/full/v22/i35/7951.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i35.7951